AMA publishes new Proprietary Laboratory Analysis (PLA) codes quarterly, and here's the batch submitted circa April 1 and ratified at the May 2024 AMA CPT editorial meeting. The new list appears July 1.
The list also includes PLA codes from recent quarters that are too recent to be in teh CY2024 AMA code book.
https://www.ama-assn.org/system/files/cpt-pla-codes-long.pdf
The codes run from 0476U (OneOme mental health / pharmacogenomic genes) to 0520U (Sync View drug monitoring from Phenomics). That suggests there are nearly 50 new PLA codes in the July 1 batch. I assume all of these were covered in the June 25, 2024 CMS public meeting for new code pricing (here).
##
AI Corner
One of the problems with PLA codes is that they have no organizing structure, and there are now over 500 of them.
I exported the PDF into Excel, and then copied the resulting 7 Excel sheets into 1 sheet. I asked CHAT GPT to make some categories and list the relevant tests. I cut and paste these below, but I have NOT manually checked them for accuracy. Initially, it happily put the Transplantation tests into its Oncology category, and I asked it to fix that.
##
ONCOLOGY:
| Code | Test and Company | Test Description |
|---|---|---|
| 0478U | Lung HDPCRTM, Protean BioDiagnostics | Oncology (non-small cell lung cancer), DNA methylation... |
| 0485U | Caris AssureTM, Caris MPI, Inc d/b/a | Oncology (solid tumor), cell-free DNA and RNA... |
| 0486U | Northstar ResponseTM, BillionToOne Labs | Oncology (pan-solid tumor), next-generation sequencing... |
| 0487U | Northstar SelectTM, BillionToOne Labs | Oncology (solid tumor), cell-free circulating tumor DNA... |
| 0490U | CELLSEARCH® Circulating Melanoma Cell | Oncology (cutaneous or uveal melanoma), circulating melanoma cells... |
| 0491U | CELLSEARCH® ER Circulating Tumor Cell (CTC) | Oncology (solid tumor), circulating tumor cells, estrogen receptor... |
| 0492U | CELLSEARCH® PD-L1 Circulating Tumor Cell | Oncology (solid tumor), circulating tumor cells, PD-L1 expression... |
| 0495U | Stockholm3, BioAgilytix Diagnostics | Oncology (prostate), analysis of circulating tumor DNA... |
| 0496U | ColoScapeTM PLUS, DiaCarta, Inc | Oncology (colorectal), cell-free DNA, 8 gene mutations... |
| 0497U | OncoAssureTM Prostate, DiaCarta, Inc | Oncology (prostate), mRNA gene-expression profiling... |
| 0498U | OptiSeqTM Colorectal Cancer NGS Panel, DiaCarta, Inc | Oncology (colorectal), next-generation sequencing... |
| 0499U | OptiSeqTM Dual Cancer Panel Kit, DiaCarta, Inc | Oncology (colorectal and lung), DNA from formalin-fixed tissue... |
| 0501U | QuantiDNATM Colorectal Cancer Triage Test, DiaCarta, Inc | Oncology (colorectal), blood, quantitative cell-free DNA... |
| 0507U | Avantect Ovarian Cancer Test, ClearNote® Health | Oncology (ovarian), DNA, whole-genome sequencing... |
| 0510U | PurISTSM, Tempus AI, Inc | Oncology (pancreatic cancer), augmentative data integration... |
| 0511U | PARIS, Tempus AI, Inc | Oncology (solid tumor), tumor cell culture and response profiling... |
| 0512U | Tempus p-MSI, Tempus AI, Inc | Oncology (prostate), augmentative algorithm for microsatellite instability... |
| 0513U | Tempus p-Prostate, Tempus AI, Inc | Oncology (prostate), augmentative algorithm for prognostic profiling... |
Transplantation:
0493U: ProsperaTM, NateraTM
- Transplantation medicine, quantification of donor-derived cell-free DNA (cfDNA) using next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA.
0508U: VitaGraftTM Kidney Baseline + 1st Plasma Test, Oncocyte Corporation
- Transplantation medicine, quantification of donor-derived cell-free DNA using 40 single-nucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cell-free DNA with risk for active rejection.
0509U: VitaGraftTM Kidney Subsequent, Oncocyte Corporation
- Transplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection.
Infectious Diseases:
- 0480U: Bacteria, Viruses, Fungus, and Parasite Metagenomic Sequencing, Spinal Fluid (MSCSF), Mayo Clinic
- Infectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next-generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen identification.
- 0483U: Ciprofloxacin Susceptibility of Neisseria gonorrhoeae, MedArbor Diagnostics, SpeeDx, Inc
- Infectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone resistance.
- 0484U: Macrolide Resistance of Mycoplasma genitalium, MedArbor Diagnostics, SpeeDx, Inc
- Infectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance.
- 0502U: QuantiVirusTM HPV E6/E7 mRNA Test for Cervical Cancer, DiaCarta, Inc
- Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched-chain capture hybridization, reported as negative or positive for high risk for HPV.
- 0504U: Urinary Tract Infection Testing, NxGen MDx LLC
- Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, real-time PCR, reported as positive or negative for each organism.
- 0505U: Vaginal Infection Testing, NxGen MDx LLC
- Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism.
